Clinical trials: Metastatic Tumor to the Bone
Prostatic Neoplasms
Incidence of Second Primary Malignancies in Prostate Cancer Patients With Bone Metastases - an Observational Retrospective Cohort Study in Sweden
This study is conducted to obtain information about prostate cancer patients with bone metastases before the end of 2013. The incidence of second primary malignancies and overall survival in patients with castration resistant…
- Trial name
- SMARCOS (NCT02963675)
- Where
- Sweden
- Volunteers
- 15,953 people
- Sponsor
- Bayer
Bone Metastases, Breast Cancer
Single Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast Cancer
Fractionated stereotatic radiation therapy (FSRT) that very precisely delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT04947280
- Testing
- Fractionated Stereotatic Radiation Therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Acute Myeloid Leukemia, Primary Myelofibrosis
A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (PMF), or MF due to polycythemia vera (PV-MF), or essential…
- Conditions
- Acute Myeloid Leukemia, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- NCT04896112
- Testing
- LNK01002
- Where
- 2 sites in United States
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Bone Neoplasms
Helical Tomotherapy as a Radiotherapy Technique for Treating Bone Metastases
To assess the safety and efficacy of a single fraction of radiotherapy using helical tomotherapy to treat bone metastases.
- Trial name
- NCT00168129
- Testing
- Helical tomotherapy
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Alberta Health services
Urothelial Carcinoma
Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy
This is a single-arm, single-site pilot of Radium-223 (55 kBq/kg) IV q3 weeks for up to 6 doses in combination with Atezolizumab 1200mg IV once every 3 weeks until investigator determined lack of benefit, unacceptable toxicity…
- Trial name
- NCT03208712
- Testing
- Atezolizumab, Radium-223
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan Rogel Cancer Center
Carcinoma, Non-Small-Cell Lung
Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
The purpose of the study was to determine the safety and test the efficacy of the combination of radium-223 dichloride and pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC) with bone metastases who either…
- Trial name
- NCT03996473
- Testing
- Radium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab
- Where
- 6 sites in United States, Belgium and 2 more
- Volunteers
- 8 people
- Sponsor
- Bayer
Metastatic Cancer, Prostate Cancer
Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis
RATIONALE: Diagnostic procedures, such as radionuclide imaging using calcium-41 (41Ca) chloride aqueous solution, may help predict progressive disease in patients with prostate cancer and bone metastasis.
- Trial name
- UCDCC#217 (NCT00918645)
- Testing
- 41 Ca
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of California, Davis
Breast Cancer, Stage IV Breast Cancer
Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases
This is a national multicenter, prospective, randomized controlled trial. The study aims to compare the 5-year overall survival (OS) between patients receiving primary tumor surgery followed by systemic therapy (surgery group)…
- Conditions
- Breast Cancer, Stage IV Breast Cancer, Bone Metastases
- Trial name
- POSITIVE-Bone (NCT07687225)
- Testing
- Primary Tumor Resection, Standard systemic therapy
- Volunteers
- 216 people
- Sponsor
- West China Hospital
Metastatic Breast Cancer, Metastatic Prostate Cancer
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
The aim of the trial is to test the hypothesis that the benefit of denosumab is maintained if administered only every 12 weeks as compared to every 4 weeks.
- Conditions
- Metastatic Breast Cancer, Metastatic Prostate Cancer, Bone Metastases
- Trial name
- NCT02051218
- Testing
- Denosumab (reduced dosing), Denosumab (standard dosing)
- Where
- 50 sites in Austria, Germany and 1 more
- Volunteers
- 1,380 people
- Sponsor
- Swiss Cancer Institute
Prostate Cancer With ≤10 Bone Metastases
Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases
The aim of this study is to evaluate the efficacy and safety of apalutamide in combination with 89Sr as neoadjuvant therapy in prostate cancer with ≤10 bone metastases.
- Trial name
- NCT05740488
- Testing
- Apalutamide, 89Sr, Luteinizing Hormone-Releasing Hormone Analog
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhujiang Hospital
Cancer, Pain
Improving Cancer Pain Management Through Self-Care
This study will test two different doses of a psychoeducational intervention to improve cancer pain management. In addition, the study will determine if the changes in pain management behaviors that the patients and family…
- Trial name
- NCT00708019
- Testing
- PRO-SELF PLUS Pain Management Program
- Where
- 2 sites in United States
- Volunteers
- 185 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
Clinical trial in breast cancer patients with bone metastases pretreated for approximately 1 year with a standard zoledronic acid regimen.
- Trial name
- NCT00320710
- Testing
- Zoledronic acid
- Where
- 92 sites in United States
- Volunteers
- 416 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Cancer, Prostate Cancer
Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008
RATIONALE: Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00084825
- Testing
- Docetaxel, Imatinib mesylate
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
The purpose of this trial is to determine the effectiveness of AMG 162 in reducing urinary N-telopeptide in advanced cancer subjects with bone metastases.
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Trial name
- NCT00104650
- Testing
- AMG 162 180 mg (SC) q 12 weeks, IV Bisphosphonate q 4 weeks, AMG 162- 180 mg q 4 weeks
- Volunteers
- 111 people
- Sponsor
- Amgen
Bony Metastases From Castrate Refractory Prostate Cancer
The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.
To describe the changes seen on bone scan and correlate them with changes in relative chemical biomarkers, patient's functional status and level of pain.
- Trial name
- NCT03368989
- Testing
- Radium-223 dichloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The University of Texas Health Science Center, Houston
Primary Breast Cancer
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
Metastatic bone disease is an important prognostic factor for survival which will in median be close to two years after first diagnosis of osseous metastases.
- Trial name
- MRD-1 (NCT00172068)
- Testing
- Zoledronic acid + Calcium/Vitamin D
- Where
- 4 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms, Bone Tissue, Pain, Intractable
Study of the Impact of the Femoral Implant "Y-strut" on Lytic Bone Metastases of the Femoral Neck (WAZA-ARY)
Bone metastases appear in many cancers. They are associated with severe pain that is refractory to standard treatment. Improving the quality of life and better pain relief is therefore an essential goal of the treatment of…
- Conditions
- Neoplasms, Bone Tissue, Pain, Intractable, Hip Fractures
- Trial name
- WAZA-ARY (NCT03887494)
- Testing
- Implantation
- Volunteers
- 15 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with pain from cancer that has spread to the bones…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04693377
- Testing
- Cryosurgery, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma, Soft Tissue Sarcoma
LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
Aspirin and low molecular weight heparin (LMWH) are both commonly employed pharmacologic methods of venous thromboembolism (VTE) prophylaxis after orthopaedic surgery.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Bone Metastases
- Trial name
- NCT03244020
- Testing
- Aspirin 325mg, Enoxaparin 40Mg/0.4mL Prefilled Syringe
- Where
- 10 sites in United States
- Volunteers
- 2,868 people
- Sponsor
- Massachusetts General Hospital
Bone Metastases in Subjects With Advanced Cancer, Radiotherapy
Timely Integration of Palliative Care in Oncology Care for Patients Referred for Palliative Radiotherapy on Bone Metastases: A Randomized Trial
Rationale: With improvements in systemic tumour-directed treatments for primary tumours, survival rates for patients with bone metastases are improving.
- Trial name
- TIPZO-RT (NCT06805396)
- Testing
- Palliative Care Consult
- Where
- 5 sites in Netherlands
- Volunteers
- 246 people
- Sponsor
- Roxanne Gal